Influvac Sub-Unit

Influenza Virus B/Austria/1359417/2021-like strain and Influenza A/Vic, the active ingredients in Influvac Sub-Unit, are subunit vaccine components presented as an injectable vaccine for intramuscular or subcutaneous use. They induce immunity to protect against seasonal influenza A and B infections in adults and eligible children. GNH USA supplies Influvac Sub-Unit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influvac Sub-Unit is a subunit influenza vaccine used to prevent infection by influenza viruses. - Influenza A (including A/Vic) infection: reduces the risk of illness, hospitalization and complications. - Influenza B (B/Austria/1359417/2021‑like) infection: lowers the chance of acquiring disease and its severe outcomes. - Seasonal influenza: provides prophylactic protection for at‑risk populations such as the elderly, healthcare workers and individuals with chronic conditions.

Common Side Effects: - Injection site pain or tenderness. - Redness or swelling at the injection site. - Low‑grade fever. - Headache. - Muscle aches (myalgia). - Fatigue.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Guillain‑Barré syndrome. - Seizures. - High fever (≥39°C). - Thrombocytopenia. - Severe local inflammation or necrosis.

Before administering Influvac Sub-Unit, consider the following precautions. - Contraindication: severe allergy to any vaccine component. - Caution: history of Guillain‑Barré syndrome after a previous influenza vaccine. - Pregnancy: limited data; use only if potential benefits outweigh risks. - Immunocompromised patients: may exhibit reduced immune response. - Age restriction: not recommended for children under 6 months. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Vaccination may be influenced by other therapies. Major Interactions (Avoid): - Concurrent administration of blood products containing antibodies: may diminish vaccine effectiveness. - Use of high‑dose immunoglobulin therapy: can interfere with immune response. Moderate Interactions (Monitor Closely): - Immunosuppressive drugs (e.g., corticosteroids, chemotherapy): may reduce antibody production. - Antipyretic or analgesic medication taken prophylactically: may mask mild post‑vaccination fever. - Live vaccines given within 4 weeks: could affect immune response to either product.